Calcineurin Inhibitor Minimisation in Renal Transplant recipients with Stable allograft function: A prospective randomised controlled trial

niversity Hospital Birmingham NHS Foundation Trust (UK)0 个研究点目标入组 90 人开始时间: 2007年8月22日最近更新: 2019年3月25日

适应症

试验速览

暂无简介。

•1. Adult recipients of a first kidney transplant
•2. A functioning kidney allograft (with estimated Glomerular Filtration Rate [eGFR] by Modification of Diet in Renal Disease [MDRD] >30 ml/min/1.73m^ 2) and be between 1 and 5 years post transplantation
•3. Stable allograft function, as defined by no greater than 10% rise in serum creatinine in the preceding 6 months, on ciclosporin and azathioprine based immunosuppression
•4. Minimal proteinuria, evidenced as urine albumin:creatinine ratio <50mg/mmol

•1. <18 years of age
•2. Pregnancy or suspicion of pregnancy confirmed by positive b-HCG pregnancy test
•3. Female patients unwilling to take effective contraception for study duration
•4. Untreated ureteric obstruction on ultrasound of allograft
•5. Recurrent urosepsis
•6. Severe systemic infection
•7. Untreated significant (>50%) renal artery stenosis on magnetic resonance angiography performed prior to study
•8. History of acute allograft rejection
•9. History of myocardial infarction
•10. History of malignancy in previous 5 years (excluding non-melanomatous tumours limited to skin)
•11. Symptomatic ischaemic heart disease
•12. Hepatitis B surface antigen positive, hepatitis C positive or HIV positive
•13. Recipient of combined organ transplantation (e.g. pancreas / kidney; liver / kidney)
•14. Recipient of ABO-incompatible kidney
•15. Greater than 1 HLA mismatch at either the ?B? or ?DR? locus
•16. Peak HLA antibody Panel Reactivity (PRA) greater than 10%
•17. Recipient who underwent HLA desensitisation procedure prior to transplantation

发起方

niversity Hospital Birmingham NHS Foundation Trust (UK)